• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

Shorter Course of Radiation Therapy Effective in Treating Men with Prostate Cancer

A new UCLA-led study shows that men with low- or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period of time and still have the same successful outcomes as from a much longer course of treatment. This type of radiation, known as stereotactic body radiotherapy, is a form of external beam radiation therapy and reduces the duration of treatment from 45 days to four-to-five days. The approach has been in use since 2000 but has not yet been widely adopted because of concerns over how safe and effective this approach would be in the long term.

Radiation Therapy

Figure shows rates of clinically significant urinary side effects, such as bleeding or obstruction (top), and clinically significant gastrointestinal side effects, such as bleeding or diarrhea (bottom), grouped by various treatment modalities. Rates of toxicity from stereotactic body radiotherapy are indicated at the bottom of each graph and appear to compare favorably with rates associated with other older and more commonly used techniques.
Graphic: Courtesy of Dr. Amar Kishan

“Most men with low- or intermediate-risk prostate cancer undergo conventional radiation, which requires them to come in daily for treatment and takes an average of nine weeks to complete,” says Amar Kishan, MD (RES ’17), assistant professor of radiation oncology and a researcher at the UCLA Jonsson Comprehensive Cancer Center. “That can be very burdensome on a patient and a huge interruption in his life. With the improvements being made to modern technology, we’ve found that using stereotactic body radiotherapy, which has a higher dose of radiation, can safely and effectively be done in a much shorter time frame without additional toxicity or compromising any chance of a cure.”

Men in the study were followed for a median of 6.9 years. Fifty-three percent of the men had low-risk disease, 32 percent had less aggressive intermediate-risk disease and 12 percent had a more aggressive form of intermediate-risk disease. The recurrence rate for men with low-risk disease was 4.5 percent, the recurrence rate for the less aggressive intermediate-risk was 8.6 percent and the recurrence rate for the more aggressive intermediate-risk group was 14.9 percent. Overall, the recurrence rate for intermediate-risk disease was 10.2 percent. These are essentially identical to rates following more conventional forms of radiation, which are about 4-to-5 percent for low-risk disease and 10-to-15 percent for intermediate-risk disease.

Researchers previously have found that stereotactic body radiation therapy was more cost effective because of the fewer treatments involved. Other research also has suggested psychological benefits, such as less regret about undergoing treatment. The current study now provides long-term data regarding the safety and clinical efficacy of this approach.

Dr. Kishan says the data show that the majority of the men followed are free of prostate cancer seven years after treatment. He added that there was no evidence that this therapy caused worse toxicity in the long term.

— Denise Heady

“Long-term Outcomes of Stereotactic Body Radiotherapy for Low-risk and Intermediate-risk Prostate Cancer,” JAMA Network Open, February 8, 2019


Previous
Critical New Clues about What Goes Awry in Brains of People with Autism
Next
Study Overturns Dogma of Cancer Metabolism Theory 8 U


YOU ARE VIEWING

Summer 2019

Summer 2019
Printable PDF
IN THIS ISSUE
  • Health Is a Human Right
  • The NICU’s Alive with the Sound of Music
  • Scientists Create a Renewable Source of Cancer-fighting T Cells
  • Fractures, Head Injuries Common in E-scooter Collisions
  • Critical New Clues about What Goes Awry in Brains of People with Autism
  • Shorter Course of Radiation Therapy Effective in Treating Men with Prostate Cancer
  • Study Overturns Dogma of Cancer Metabolism Theory 8 U
  • Electrical Activity Early in Fruit Flies’ Brain Development Could Shed Light on How Neurons Wire the Brain
  • The Demedicalization of Mental Illness
  • Brain Chat: Baljit S. Khakh, PhD
  • Expanded Interview: Baljit S. Khakh, PhD
  • A New Kind of House Call
  • Stepping Back from the Edge
  • Healing Is the Goal
  • Awards & Honors
  • In Memoriam
  • HOSTs Extend Help to Medical Students Interviewing for Residency
  • UCLA Celebrates the Philanthropy of Laurie and Steven Gordon
  • A Fitting Tribute: The Garry Shandling Learning Studio
  • Project to Improve the End-of-Life Experience Marks Its First Anniversary
  • UCLA Center for East-West Medicine Celebrates 25 Years
  • Philanthropy Advances Stroke Care and Honors Dr. Wally Ghurabi
  • Grey Matters Event Sheds Light on Memories
  • UCLA Celebrates Lasker Award-recipient Dr. Michael Grunstein
  • Epilepsy Foundation Endows Fellowship Program in UCLA Pediatrics
  • TEDxUCLA Salon Tackles Depression
  • UCLA Cardiovascular Theme Hosts Innovations in Heart and Lung Transplantation Event
  • Lunch with the Scientists Celebrates Research Accomplishments
  • UCLA Head and Neck Surgery Celebrates Calcaterra Family’s Philanthropy and the Inaugural Calcaterra Chair Holder
  • Gifts
  • In Memoriam
  • Mosquitoes, Malaria and Me
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth

Learn more about myUCLAhealth